SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023

Yaniv Lustig, Michal Canetti, Victoria Indenbaum, Yovel Peretz, Yael Weiss-Ottolenghi, Ili Margalit, Keren Asraf, Tal Levin, Neta Zuckerman, Enosh Tomer, Michal Mandelboim, Ram Doolman, Noam Barda, Gili Regev-Yochay

Research output: Contribution to journalArticlepeer-review

Abstract

Although a vaccine against SARS-CoV-2 Omicron-XBB.1.5 variant is available worldwide and recent infection is protective, the lack of recorded infection data highlights the need to assess variant-specific antibody neutralization levels. We analyzed IgG levels against receptor-binding domain-specific SARS-CoV-2 ancestral strain as a correlate for high neutralizing titers against XBB variants.

Original languageEnglish
Pages (from-to)1050-1052
Number of pages3
JournalEmerging Infectious Diseases
Volume30
Issue number5
DOIs
StatePublished - 1 May 2024

Keywords

  • antibodies
  • COVID-19
  • IgG
  • Israel
  • neutralizing antibodies
  • respiratory infections
  • SARS-CoV-2
  • vaccine-preventable diseases
  • vaccines
  • viruses
  • XBB variant

Fingerprint

Dive into the research topics of 'SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023'. Together they form a unique fingerprint.

Cite this